RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer

In metastatic colorectal cancer, RAS and BRAF mutations cause resistance to anti‐EGFR therapies, such as cetuximab. Heterogeneity in RAS and BRAF mutations might explain nonresponse in a subset of patients receiving cetuximab. Analyzing mutations in plasma‐derived circulating tumor DNA (ctDNA) could...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Oncol
Main Authors: van Helden, Erik J., Angus, Lindsay, Menke‐van der Houven van Oordt, C. Willemien, Heideman, Daniëlle A. M., Boon, Eline, van Es, Suzanne C., Radema, Sandra A., van Herpen, Carla M. L., de Groot, Derk Jan A., de Vries, Elisabeth G. E., Jansen, Maurice P. H. M., Sleijfer, Stefan, Verheul, Henk M. W.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2019
Assuntos:
Research Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6822250/
https://ncbi.nlm.nih.gov/pubmed/31350822
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12550
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares